AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Lilly's US Bamlanivimab Contract Raises Difficult Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Torrent Expects Indian Dapagliflozin Ruling In Q3
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.
Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma